GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are indicated for treatment of type 2 diabetes since they mimic the actions of native GLP‐1 on pancreatic islet cells, stimulating insulin release, while inhibiting glucagon release, in a glucose‐dependent manner. The observation of weight loss has led to exploration of their potential as antiobesity agents, with liraglutide 3.0 mg day−1 approved for weight management in the US on December 23, 2014, and in the EU on March 23, 2015. This review examines the potential nonglycemic effects of GLP‐1 receptor agonists.

• Publication year

  2015

• Venue

  Obesity

• Publication date

  2015-05-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/oby.21107PMID 25959380PMCID 4692091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial

  2015cited by this paper
• Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

  2015cited by this paper
• Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial

  2015cited by this paper
• Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J)

  2015influential reference
• Long-term drug treatment for obesity: a systematic and clinical review.

  2014cited by this paper
• Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency.

  2014cited by this paper
• Obesity and neuroinflammation: a pathway to cognitive impairment.

  2014cited by this paper
• Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

  2014cited by this paper
• Recent advances in clinical practice challenges and opportunities in the management of obesity

  2014cited by this paper
• The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

  2014cited by this paper
• Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

  2014cited by this paper
• Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

  2014cited by this paper
• Relationships between diabetes and cognitive impairment.

  2014cited by this paper
• Effects of GLP-1 in the Kidney

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014influential reference
• Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

  2014cited by this paper
• Named Series : Diet , Inflammation and the Brain Obesity and neuroinflammation : A pathway to cognitive impairment

  2014cited by this paper
• Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

  2014cited by this paper
• Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

  2014cited by this paper
• The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

  2014cited by this paper
• HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

  2014cited by this paper
• Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial

  2014cited by this paper
• Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials

  2014cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013influential reference
• Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

  2013cited by this paper
• Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes?

  2013cited by this paper
• The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.

  2013cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on renal function.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

  2013cited by this paper
• Exenatide and the treatment of patients with Parkinson's disease.

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

  2013cited by this paper
• Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

  2013influential reference
• The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

  2013cited by this paper
• Is there a place for incretin therapies in obesity and prediabetes?

  2013cited by this paper
• The Neuroprotection of Liraglutide on Alzheimer-Like Learning and Memory Impairment by Modulating the Hyperphosphorylation of Tau and Neurofilament Proteins and Insulin Signaling Pathways in Mice

  2013cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Changes in taste perception and eating behavior after bariatric surgery-induced weight loss in women

  2013cited by this paper
• Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

  2013cited by this paper
• Abdominal and Total Adiposity and The Risk of Acute Pancreatitis: A Population-Based Prospective Cohort Study

  2013cited by this paper
• Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

  2013cited by this paper
• Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• Potential of incretin-based therapies for non-alcoholic fatty liver disease.

  2013cited by this paper
• Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

  2013cited by this paper
• Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.

  2013cited by this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cited by this paper
• Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.

  2012cited by this paper
• Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• Short communication: expression of peptide YY, proglucagon, neuropeptide Y receptor Y2, and glucagon-like peptide-1 receptor in bovine peripheral tissues.

  2012cited by this paper
• Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity

  2012cited by this paper
• Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes

  2012cited by this paper
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  2012cited by this paper
• Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

  2012cited by this paper
• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

  2012cited by this paper
• Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

  2012cited by this paper
• Exenatide exerts a potent antiinflammatory effect.

  2012cited by this paper
• GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

  2012cited by this paper
• The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.

  2012cited by this paper
• The effect of glucagon-like peptide 1 on cardiovascular risk

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

  2011cited by this paper
• Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

  2011cited by this paper
• Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Regulation of glucagon secretion by incretins

  2011cited by this paper
• The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study

  2011cited by this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

  2011cited by this paper
• Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

  2011cited by this paper
• Neuroprotective properties of GLP-1: theoretical and practical applications

  2011cited by this paper
• Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.

  2011influential reference
• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  2011influential reference
• Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

  2010cited by this paper
• Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

  2010cited by this paper
• Bariatric surgery and taste: novel mechanisms of weight loss

  2010cited by this paper
• GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

  2010cited by this paper
• Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

  2010cited by this paper
• Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

  2010cited by this paper
• Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

  2010cited by this paper
• Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

  2010cited by this paper
• Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

  2010cited by this paper
• Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

  2010cited by this paper
• Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

  2010cited by this paper
• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

  2009cited by this paper
• Modulation of Taste Sensitivity by GLP‐1 Signaling in Taste Buds

  2009cited by this paper
• Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

  2009cited by this paper
• Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones.

  2009cited by this paper
• Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes

  2009cited by this paper
• Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

  2008cited by this paper
• Modulation of taste sensitivity by GLP‐1 signaling

  2008influential reference
• Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes

  2007cited by this paper
• Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

  2007cited by this paper
• T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1

  2007cited by this paper
• Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

  2007cited by this paper
• Colocalization of the α-subunit of gustducin with PYY and GLP-1 in L cells of human colon

  2006cited by this paper

• PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS: A LITERATURE REVIEW

  2026cites this paper
• Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States.

  2026cites this paper
• Is Bariatric Surgery at Risk Due to Semaglutide?

  2025cites this paper
• Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence

  2025cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis

  2025influential citation
• Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom

  2025cites this paper
• Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.

  2025cites this paper
• GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review

  2025cites this paper
• The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence

  2025cites this paper
• Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

  2025cites this paper
• Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice

  2025cites this paper
• Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study

  2025cites this paper
• Use of Semaglutide in Diabetes Care Post Renal Transplantation

  2025cites this paper
• Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study

  2025cites this paper
• 2024 Thai guidelines on the treatment of hypertension

  2025cites this paper
• Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon-Like Peptide-1 Receptor Agonists - A Review.

  2024cites this paper
• A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure

  2024cites this paper
• Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials

  2024cites this paper
• The Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?

  2024cites this paper
• Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review

  2024cites this paper
• Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges

  2024cites this paper
• From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists

  2024cites this paper
• Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

  2024cites this paper
• Kidney function evaluation in children and adolescents with obesity: a not-negligible need

  2024cites this paper
• The Metabolic and Endocrine Effects of a 12-Week Allulose-Rich Diet

  2024cites this paper
• Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus

  2024influential citation
• Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy

  2024cites this paper
• Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

  2024cites this paper
• Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures

  2024cites this paper
• Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects

  2023cites this paper
• New advances of adiponectin in regulating obesity and related metabolic syndromes

  2023cites this paper
• Efficacy and safety of glucagon-like-peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis.

  2023cites this paper
• Efficacy and Tolerability of Semaglutide in Patients With Type-2 Diabetes Mellitus: Experience of a Tertiary Care Hospital, Pakistan

  2023cites this paper
• Liraglutide modulates morpho‐functional and inflammatory gastrointestinal responses in rats

  2023influential citation
• Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice

  2023cites this paper
• Sustained metabolic benefits of ΔTRTX‐Ac1, a tarantula venom‐derived peptide, when administered together with exenatide in high‐fat fed mice

  2023cites this paper
• Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature

  2023cites this paper
• Mechanism of metabolic surgery for the treatment of Type 2 Diabetes Mellitus (T2DM)

  2023cites this paper
• Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

  2023cites this paper
• Liraglutide protects against diastolic dysfunction and improves ventricular protein translation

  2023cites this paper
• Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective

  2023cites this paper
• Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes

  2023cites this paper
• A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

  2022cites this paper
• The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism

  2022influential citation
• Eugenol alleviated nonalcoholic fatty liver disease in rat via a gut-brain-liver axis involving glucagon-like Peptide-1.

  2022cites this paper
• Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

  2022cites this paper
• The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome

  2022cites this paper
• A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients

  2022cites this paper
• DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

  2022cites this paper
• Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

  2022cites this paper
• Pharmacotherapy for Essential Hypertension: A Brief Review

  2022cites this paper
• Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in mice

  2022cites this paper
• Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.

  2021cites this paper
• Expression of obesity-related genes in testes and sperm of rats subjected to caloric restriction and to GLP-1 administration

  2021cites this paper
• Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

  2021cites this paper
• Drugs for Treating Obesity.

  2021cites this paper
• Role of Enteroendocrine Hormones in Appetite and Glycemia.

  2021cites this paper
• The Role of Gasotransmitters in Gut Peptide Actions

  2021cites this paper
• Exercise, Pharmaceutical Therapies and Type 2 Diabetes: Looking beyond Glycemic Control to Whole Body Health and Function

  2021cites this paper
• GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date

  2020cites this paper
• Efficacy of Liraglutide in clinical practice: Single centre experience

  2020cites this paper
• Noninsulin Therapy for Diabetes

  2020cites this paper
• Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

  2020cites this paper
• Functional Study on the GLP-1 Based Drug Liraglutide in High Fat Diet Fed Mice

  2020cites this paper
• Obesity and Bariatric Surgery

  2020cites this paper
• Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients

  2020cites this paper
• Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers

  2020cites this paper
• Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease

  2020cites this paper
• Effects of newly introduced antidiabetic drugs on autophagy.

  2019cites this paper
• Eicosapentaenoic acid/arachidonic acid ratio and weight loss during hospitalization for glycemic control among overweight Japanese patients with type 2 diabetes: a retrospective observational study

  2019cites this paper
• A hosszú hatású GLP-1-receptoragonisták helye a 2-es típusú diabetes kezelésében – a jelen hazai lehetőségek

  2019cites this paper
• The use of SGL T2 inhibitors and GLP-1 receptor agonists, a worthwhile physiologic combination in managing type 2 diabetes while reducing cardiovascular risk

  2019cites this paper
• Diabetic kidney diseases revisited: A new perspective for a new era

  2019cites this paper
• Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!

  2019cites this paper
• Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?

  2019cites this paper
• Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force

  2019cites this paper
• Glucagon, GLP-1 and Thermogenesis

  2019cites this paper
• Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus

  2018cites this paper
• Enquête sur la prise en charge des patients diabétiques de type 2 par les médecins généralistes en Bourgogne. Implications pour l’enseignement post-universitaire

  2018cites this paper
• Glucagon-like Receptor 1 Agonists in the Treatment of Type 2 Diabetes

  2018cites this paper
• Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?

  2018cites this paper
• Clinical and Investigative Endocrinology and Diabetes.

  2018cites this paper
• Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study

  2018cites this paper
• Cardiovascular outcomes and safety with antidiabetic drugs

  2018cites this paper
• Involvement of TRPV1 Channels in Energy Homeostasis

  2018cites this paper
• Time Course of Blood Pressure Decrease After Bariatric Surgery in Normotensive and Hypertensive Patients

  2018cites this paper
• Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits

  2018cites this paper
• Obesity-related, metabolic asthma: a new role for glucagon-like peptide 1 agonists.

  2017cites this paper
• Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.

  2017cites this paper
• Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.

  2017cites this paper
• After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

  2017cites this paper
• Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps

  2017cites this paper
• Discontinued drug therapies to treat diabetes in 2015

  2017cites this paper
• Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists

  2016cites this paper
• Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

  2016cites this paper
• Cardiovascular safety of anti-diabetic drugs.

  2016cites this paper
• Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications

  2016cites this paper
• Natural Products with Anti-obesity Effects and Different Mechanisms of Action.

  2016cites this paper
• Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

  2016cites this paper
• Role of glucagon-like peptide 1 receptor agonists in management of obesity.

  2016cites this paper